Search Results - "Patel, Shreyaskumar R"

An updated review of the treatment landscape for advanced gastrointestinal stromal tumors.

Authors: Patel, Shreyaskumar R. Reichardt, Peter

Source: Cancer (0008543X). Jul2021, Vol. 127 Issue 13, p2187-2195. 9p.

Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.

Authors: Hensley, Martee L. Patel, Shreyaskumar R. von Mehren, Margaret et al.

Source: Gynecologic Oncology. Sep2017, Vol. 146 Issue 3, p531-537. 7p.

Chemotherapy for soft tissue sarcoma.

Authors: Ratan, Ravin Patel, Shreyaskumar R.

Source: Cancer (0008543X). Oct2016, Vol. 122 Issue 19, p2952-2960. 10p.

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

Authors: Schöffski, Patrick Chawla, Sant Maki, Robert G. et al.

Source: Lancet. 4/16/2016, Vol. 387 Issue 10028, p1629-1637. 9p.

Subjects: Drug efficacy, Eribulin, Dacarbazine, Liposarcoma, Soft tissue injuries, Therapeutics, Antineoplastic agents, Clinical trials, Comparative studies, Heterocyclic compounds, Ketones, Research methodology, Medical cooperation, Research, Soft tissue tumors, Survival analysis (Biometry), Evaluation research, Randomized controlled trials, Treatment effectiveness, Leiomyosarcoma, Tumor grading

Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor.

Authors: Park, Min S. Patel, Shreyaskumar R. Ludwig, Joseph A. et al.

Source: Cancer (0008543X). Nov2011, Vol. 117 Issue 21, p4939-4947. 9p.

Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.

Authors: Jones, Robin L. Herzog, Thomas J. Patel, Shreyaskumar R. et al.

Source: Cancer Medicine. Jun2021, Vol. 10 Issue 11, p3565-3574. 10p.

Primary Intrathoracic Synovial Sarcoma: An Analysis of Outcomes of This Rare Disease.

Authors: Patel, Riddhi R. Bishop, Andrew J. Lazar, Alexander J. et al.

Source: Cancers. Mar2025, Vol. 17 Issue 5, p745. 15p.

Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies: A single-institution cohort.

Authors: Nakazawa, Michael S Livingston, J Andrew Zarzour, Maria A et al.

Source: Rare Tumors. 8/4/2024, p1-9. 9p.

Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin.

Authors: Jones, Robin L. Maki, Robert G. Patel, Shreyaskumar R. et al.

Source: Cancer (0008543X). 12/15/2019, Vol. 125 Issue 24, p4435-4441. 7p.

High-dose ifosfamide-induced exacerbation of peripheral neuropathy.

Authors: Patel, Shreyaskumar R. Forman, Arthur D.

Source: JNCI: Journal of the National Cancer Institute. 2/16/94, Vol. 86 Issue 4, p305. 2p.

Chemotherapy for Bone Sarcoma in Adults.

Authors: Wagner, Michael J. Livingston, J. Andrew Patel, Shreyaskumar R. et al.

Source: Journal of Oncology Practice. Mar2016, Vol. 12 Issue 3, p208-216. 10p.

Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Authors: Keung, Emily Z. Lazar, Alexander J. Torres, Keila E. et al.

Source: BMC Cancer. 9/24/2018, Vol. 18 Issue 1, p1-7. 7p. 2 Diagrams, 1 Chart.

Is there a role for surgery in patients with “unresectable” cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?

Authors: Scaife, Courtney L. Hunt, Kelly K. Patel, Shreyaskumar R. et al.

Source: American Journal of Surgery. Dec2003, Vol. 186 Issue 6, p665-669. 5p.

Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes.

Authors: Roszik, Jason Wei-Lien Wang Livingston, John A. et al.

Source: Clinical Sarcoma Research. 6/15/2017, Vol. 7, p1-7. 7p.

Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience.

Authors: Wang, Zhijie Shi, Naiyi Naing, Aung et al.

Source: Cancer Medicine. Dec2016, Vol. 5 Issue 12, p3437-3444. 8p.

Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study.

Authors: Ravi, Vinod Subramaniam, Aparna Zheng, Jing et al.

Source: Cancer (0008543X). Sep2022, Vol. 128 Issue 18, p3383-3391. 9p.

Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321.

Authors: Avutu, Viswatej Weiss, Aaron R. Reed, Damon R. et al.

Source: Journal of Adolescent & Young Adult Oncology. Jun2022, Vol. 11 Issue 3, p328-332. 5p.

Real‐world outcomes of patients with locally advanced or metastatic epithelioid sarcoma.

Authors: Gounder, Mrinal M. Merriam, Priscilla Ratan, Ravin et al.

Source: Cancer (0008543X). Apr2021, Vol. 127 Issue 8, p1311-1317. 7p.

Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report.

Authors: Conley, Anthony P. Trinh, Van Anh Zobniw, Chrystia M. et al.

Source: Journal of Global Oncology. 2018, p1-6. 6p. 1 Black and White Photograph, 1 Chart.

Clinical trial enrollment of adolescents and young adults with sarcoma.

Authors: Davis, Lara E. Janeway, Katherine A. Weiss, Aaron R. et al.

Source: Cancer (0008543X). Sep2017, Vol. 123 Issue 18, p3434-3440. 7p.